Targeted treatments in fragile X syndrome

Bibliography

• Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009;85(4):503-14
   PubMed Web of Science ®Google Scholar
• Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3(5):359-71
   PubMed Web of Science ®Google Scholar
• Tassone F, Iong KP, Tong T-H, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the united states. Genome Med 2012;4(12):100
   PubMedGoogle Scholar
• Hagerman RJ, Hagerman PJ. Fragile X syndrome: diagnosis, treatment, and research. JHU Press, Baltimore; 2002
   Google Scholar
• Roberts JE, Weisenfeld LAH, Hatton DD, et al. Social approach and autistic behavior in children with fragile X syndrome. J Autism Dev Disord 2007;37(9):1748-60
   Google Scholar
• Sullivan K, Hatton D, Hammer J, et al. ADHD symptoms in children with FXS. Am J Med Genet A 2006;140(21):2275-88
   PubMedGoogle Scholar
• Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr 2009;56:165-86
   Google Scholar
• Kronk R, Bishop EE, Raspa M, et al. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep 2010;33(5):679
   Google Scholar
• Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72(4):869-78
   PubMed Web of Science ®Google Scholar
• Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the fmr1 premutation and fragile X -associated tremor/ataxia syndrome. Lancet Neurol 2013;12(8):786-98
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med 2011;29(4):299-307
   PubMed Web of Science ®Google Scholar
• Roberts JE, Bailey DB, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009;150(1):130-9
   Google Scholar
• Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011;72(2):175
   PubMed Web of Science ®Google Scholar
• Hagerman P. Fragile X -associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol 2013;126(1):1-19
   PubMed Web of Science ®Google Scholar
• Hessl D, Wang JM, Schneider A, et al. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry 2011;70(9):859-65
   PubMed Web of Science ®Google Scholar
• Rodriguez-Revenga L, Madrigal I, Alegret M, et al. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008;18(4):153-5
   Google Scholar
• Seritan AL, Bourgeois JA, Schneider A, et al. Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Curr Psychiatr Rev 2013;9(1):65-71
   Google Scholar
• Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 2012;122(12):4314
   PubMed Web of Science ®Google Scholar
• Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective rna binding. Science 1993;262(5133):563-6
   PubMed Web of Science ®Google Scholar
• Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011;146(2):247-61
   PubMed Web of Science ®Google Scholar
• Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012;74(2):285-99
   PubMed Web of Science ®Google Scholar
• Fatemi S, Folsom T, Rooney R, Thuras P. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013;3(6):e271
   Google Scholar
• Massey PV, Bashir ZI. Long-term depression: multiple forms and implications for brain function. Trends Neurosci 2007;30(4):176-84
   Google Scholar
• Bear MF, Huber KM, Warren ST. The mGLuR theory of fragile X mental retardation. Trends Neurosci 2004;27(7):370-7
   PubMed Web of Science ®Google Scholar
• Dölen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010;127(1):78-93
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord 2011;3(3):193-210
   Google Scholar
• Gross C, Nakamoto M, Yao X, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010;30(32):10624-38
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Kaphzan H, Alvarez-Dieppa Amanda C, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012;76(2):325-37
   PubMed Web of Science ®Google Scholar
• Padgett CL, Slesinger PA. GABAB receptor coupling to g-proteins and ion channels. Adv Pharmacol 2010;58:123-47
   PubMedGoogle Scholar
• Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005;6(3):215-29
   PubMed Web of Science ®Google Scholar
• Cardin JA, Carlén M, Meletis K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 2009;459(7247):663-7
   Google Scholar
• Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X :leading the way for targeted treatments in autism. Neurotherapeutics 2010;7(3):264-74
   PubMed Web of Science ®Google Scholar
• Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009;459(7247):698-702
   PubMed Web of Science ®Google Scholar
• Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 2006;9(10):1221-5
   Google Scholar
• Rubenstein J, Merzenich M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003;2(5):255-67
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile X syndrome. Curr Paediatr 2002;12(4):316-24
   Google Scholar
• Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123(1):378-90
   PubMed Web of Science ®Google Scholar
• Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of dsm-iv anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011;3(1):57-67
   Google Scholar
• D'Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006;1121(1):238-45
   PubMedGoogle Scholar
• lmos-Serrano JL, Paluszkiewicz SM, Martin BS, et al. Defective gabaergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010;30(29):9929-38
   Google Scholar
• Curia G, Papouin T, Séguéla P, Avoli M. Downregulation of tonic gabaergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009;19(7):1515-20
   PubMed Web of Science ®Google Scholar
• Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in gabaergic protein expression in fragile X knockout mice. Neuropharmacology 2010;59(3):167-71
   Google Scholar
• Liao W-H, Van Den Abbeele T, Herman P, et al. Expression of NMDA, AMPA and GABA(A) receptor subunit mrnas in the rat auditory brainstem. II. Influence of intracochlear electrical stimulation. Hear Res 2000;150(1):12-26
   Google Scholar
• D'Hulst C, Heulens I, Brouwer JR, et al. Expression of the gabaergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res 2009;1253:176-83
   Web of Science ®Google Scholar
• Kooy FR. Of mice and the fragile X syndrome. Trends Genet 2003;19(3):148-54
   Google Scholar
• Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. In: Denman RB, editor, Modeling fragile X syndrome. Volume 54. Springer, Berlin Heidelberg; 2012. p. 297-335
   Google Scholar
• Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012;76(2):325-37
   PubMed Web of Science ®Google Scholar
• Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron 2007;56(6):955-62
   PubMed Web of Science ®Google Scholar
• Zang JB, Nosyreva ED, Spencer CM, et al. A mouse model of the human fragile X syndrome I304n mutation. PLoS Genet 2009;5(12):e1000758
   Google Scholar
• Dockendorff TC, Su HS, McBride SMJ, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002;34(6):973-84
   PubMed Web of Science ®Google Scholar
• McBride SM, Holloway SL, Jongens TA. Using drosophila as a tool to identify pharmacological therapies for fragile X syndrome. Drug Discov Today Technol 2013;10(1):e129-36
   Google Scholar
• Siller SS, Broadie K. Neural circuit architecture defects in a drosophila model of fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011;4(5):673-85
   Google Scholar
• Zhang YQ, Broadie K. Fathoming fragile X in fruit flies. Trends Genet 2005;21(1):37-45
   PubMed Web of Science ®Google Scholar
• McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a drosophila model of fragile X syndrome. Neuron 2005;45(5):753-64
   PubMed Web of Science ®Google Scholar
• Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49(7):1053-66
   PubMed Web of Science ®Google Scholar
• de Vrij FMS, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in fmr1 ko mice. Neurobiol Dis 2008;31(1):127-32
   PubMed Web of Science ®Google Scholar
• Chuang SC, Zhao W, Bauchwitz R, et al. Prolonged epileptiform discharges induced by altered group i metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 2005;25(35):8048-55
   Google Scholar
• Yuskaitis CJ, Mines MA, King MK, et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010;79(4):632-46
   PubMed Web of Science ®Google Scholar
• Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group i metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci USA 2005;102(6):2180-5
   Google Scholar
• Nakamoto M, Nalavadi V, Epstein MP, et al. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of ampa receptors. Proc Natl Acad Sci USA 2007;104(39):15537-42
   Google Scholar
• Meredith RM, de Jong R, Mansvelder HD. Functional rescue of excitatory synaptic transmission in the developing hippocampus in fmr1-ko mouse. Neurobiol Dis 2011;41(1):104-10
   Google Scholar
• Lea PM IV, Movsesyan VA, Faden AI. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol 2005;145(4):527-34
   Google Scholar
• Levenga J, Hayashi S, de Vrij FMS, et al. Afq056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011;42(3):311-17
   Google Scholar
• Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74(1):49-56
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46(4):266-71
   PubMed Web of Science ®Google Scholar
• Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3(64):64ra61
   Google Scholar
• Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in drosophila. Nat Chem Biol 2008;4(4):256-63
   Google Scholar
• Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the gabaergic system and circuit dysfunction. Dev Neurosci 2011;33(5):349-64
   Google Scholar
• Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of gabab receptors with arbaclofen. Sci Transl Med 2012;4(152):152ra128
   Web of Science ®Google Scholar
• Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127
   PubMed Web of Science ®Google Scholar
• Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012;42(7):1377-92
   Google Scholar
• Heulens I, D'Hulst C, Van Dam D, et al. Pharmacological treatment of fragile X syndrome with gabaergic drugs in a knockout mouse model. Behav Brain Res 2012;229(1):244-9
   Google Scholar
• Idrissi A, Boukarrou L, Dokin C, Brown WT. Taurine improves congestive functions in a mouse model of fragile X syndrome. In: Azuma J, Schaffer S, Ito T, editors, Taurine 7. Volume 643. Springer, New York; 2009. p. 191-8
   Google Scholar
• Erickson C, Wink L, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013;228(1):75-84
   PubMedGoogle Scholar
• Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009;46(2):94-102
   PubMed Web of Science ®Google Scholar
• Michaluk P, Wawrzyniak M, Alot P, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011;124(19):3369-80
   Google Scholar
• Rotschafer SE, Trujillo MS, Dansie LE, et al. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile X syndrome. Brain Res 2012;1439:7-14
   Google Scholar
• Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010;115(5):433-43
   Google Scholar
• Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10(1):91
   PubMed Web of Science ®Google Scholar
• Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013;34(3):147-55
   PubMed Web of Science ®Google Scholar
• Choi CH, McBride SM, Schoenfeld BP, et al. Age-dependent cognitive impairment in a drosophila fragile X model and its pharmacological rescue. Biogerontology 2010;11(3):347-62
   PubMed Web of Science ®Google Scholar
• Liu ZH, Chuang DM, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X yndrome. Int J Neuropsychopharmacol 2011;4(5):618-30
   Google Scholar
• King MK, Jope RS. Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav 2013;12(7):723-31
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008;29(4):293-302
   PubMed Web of Science ®Google Scholar
• Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011;45(4):241-5
   Google Scholar
• Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 2010;30(46):15616-27
   PubMed Web of Science ®Google Scholar
• Osterweil EK, Chuang S-C, Chubykin AA, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013;77(2):243-50
   Google Scholar
• Cartagena CM, Phillips KL, Williams GL, et al. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med 2013;15(3):504-14
   Google Scholar
• Manor I, Newcorn JH, Faraone SV, Adler LA. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med 2013;125(4):181-90
   PubMed Web of Science ®Google Scholar
• Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013;161a(8):1897-903
   Google Scholar
• Schneider A, Leigh MJ, Adams P, et al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol 2013;27(10):956-63
   Google Scholar
• Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord 2011;3(3):211-24
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=9926832. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9926832 [Accessed 15 December 2013]
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID= 44602. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=44602 [Accessed 15 December 2013]
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID= 6918305. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918305 [Accessed 15 December 2013]
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=54675783. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54675783 [Accessed 15 December 2013]
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=53232. Available from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53232 [Accessed 15 December 2013]
   Google Scholar
• Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006;16(5):525-40
   Google Scholar